Dugma-on, Mary Ann .

HRN: 23-20-66  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/19/2023
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
06/21/2023
06/27/2023
IV
500mg
Q8
Sp LTCS, Thickly Msaf
Waiting Final Action 

Indication:  Prophylaxis    Type of Infection:  Reproductive Tract    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: